The Severity of COVID 19 Pneumonia in Vaccinated vs. Non-vaccinated Patients in the Second Wave: An Experience From a Tertiary Care Center in India.
comorbidities
covid 19
oxygen therapy
severity
vaccination
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
25
05
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
2
7
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by SARS CoV-2 that emerged in Wuhan, China, and has rapidly spread worldwide. The mortality rate of critically ill COVID-19 patients is high. To assess the severity, different clinical symptoms, and comorbidities of COVID-19 pneumonia in vaccinated vs. non-vaccinated patients. In this single-center, cross-sectional study, 142 patients with COVID-19 were enrolled. The clinical characteristics, comorbidities, severity, and outcomes were also assessed. Of the 142 patients, 92 (64.8%) were males, with a mean age of (56.00±14.81) years. Among them, 62 (43.7%) were aged above 60 years. Of these, 92 (64.7%) had comorbidities. The patients were divided into two groups: unvaccinated and those who received at least one dose of the vaccine within six months. The demographic characteristics of the two groups were similar except for gender. In the vaccinated group, most of the patients were males. Most patients in the non-vaccinated group had a severe illness, whereas most patients in the vaccinated group had mild to moderate disease. Only 26% of the vaccinated group experienced severe illness compared to 71.5% in the unvaccinated group. In addition, the all-cause 30-day mortality in the non-vaccinated population was higher than that in the vaccinated population. However, this difference was not statistically significant (12.5% vs. 7.1%). On the contrary, there was no difference in the length of the intensive care unit or total hospital stay between the two groups. Severe COVID-19 had the worst outcome in the unvaccinated patients. Most partially vaccinated patients got infected before developing immunity, and a small percentage of completely immunized patients who were infected were likely non-responders. Receiving at least one vaccination dose significantly reduced illness severity.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by SARS CoV-2 that emerged in Wuhan, China, and has rapidly spread worldwide. The mortality rate of critically ill COVID-19 patients is high.
OBJECTIVE
OBJECTIVE
To assess the severity, different clinical symptoms, and comorbidities of COVID-19 pneumonia in vaccinated vs. non-vaccinated patients.
METHODS
METHODS
In this single-center, cross-sectional study, 142 patients with COVID-19 were enrolled. The clinical characteristics, comorbidities, severity, and outcomes were also assessed.
RESULTS
RESULTS
Of the 142 patients, 92 (64.8%) were males, with a mean age of (56.00±14.81) years. Among them, 62 (43.7%) were aged above 60 years. Of these, 92 (64.7%) had comorbidities. The patients were divided into two groups: unvaccinated and those who received at least one dose of the vaccine within six months. The demographic characteristics of the two groups were similar except for gender. In the vaccinated group, most of the patients were males. Most patients in the non-vaccinated group had a severe illness, whereas most patients in the vaccinated group had mild to moderate disease. Only 26% of the vaccinated group experienced severe illness compared to 71.5% in the unvaccinated group. In addition, the all-cause 30-day mortality in the non-vaccinated population was higher than that in the vaccinated population. However, this difference was not statistically significant (12.5% vs. 7.1%). On the contrary, there was no difference in the length of the intensive care unit or total hospital stay between the two groups.
CONCLUSION
CONCLUSIONS
Severe COVID-19 had the worst outcome in the unvaccinated patients. Most partially vaccinated patients got infected before developing immunity, and a small percentage of completely immunized patients who were infected were likely non-responders. Receiving at least one vaccination dose significantly reduced illness severity.
Identifiants
pubmed: 35774652
doi: 10.7759/cureus.25378
pmc: PMC9236633
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e25378Informations de copyright
Copyright © 2022, Bajpai et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Ann Med Surg (Lond). 2021 Nov;71:102951
pubmed: 34667593
Lancet Infect Dis. 2022 Jan;22(1):43-55
pubmed: 34480857
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
JAMA. 2021 Aug 10;326(6):473
pubmed: 34374736
Hum Vaccin Immunother. 2021 Dec 2;17(12):5024-5029
pubmed: 34847815
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
Epidemiol Infect. 2021 Oct 11;149:e224
pubmed: 34632972
Elife. 2021 Apr 08;10:
pubmed: 33830018
Vaccines (Basel). 2021 Jul 13;9(7):
pubmed: 34358197
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657
pubmed: 34245907
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet. 2021 Apr 10;397(10282):1326-1327
pubmed: 33798497